In last trading session, Capricor Therapeutics Inc (NASDAQ:CAPR) saw 4.39 million shares changing hands with its beta currently measuring 0.79. Company’s recent per share price level of $7.67 trading at $0.37 or 5.07% at ring of the bell on the day assigns it a market valuation of $350.34M. That closing price of CAPR’s stock is at a discount of -205.08% from its 52-week high price of $23.40 and is indicating a premium of 54.11% from its 52-week low price of $3.52. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.05 million shares which gives us an average trading volume of 1.86 million if we extend that period to 3-months.
For Capricor Therapeutics Inc (CAPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.48 in the current quarter.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Upright in the green during last session for gaining 5.07%, in the last five days CAPR remained trading in the green while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $7.67 price level, adding 10.5% to its value on the day. Capricor Therapeutics Inc’s shares saw a change of -44.42% in year-to-date performance and have moved 11.32% in past 5-day. Capricor Therapeutics Inc (NASDAQ:CAPR) showed a performance of -18.40% in past 30-days. Number of shares sold short was 10.34 million shares which calculate 7.12 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 48.87% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 21.5. It follows that stock’s current price would drop -30.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -30.38% for stock’s current value.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
This year revenue growth is estimated to rise 158.53% from the last financial year’s standing.
And 3 analysts are in estimates of company making revenue of 19.67M in the next quarter. Company posted 3.97M and 2.26M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.01% during past 5 years.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
Insiders are in possession of 16.81% of company’s total shares while institution are holding 38.78 percent of that, with stock having share float percentage of 46.61%. Investors also watch the number of corporate investors in a company very closely, which is 38.78% institutions for Capricor Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CAPR for having 1.63 million shares of worth $7.77 million. And as of 2024-06-30, it was holding 5.1145 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.55 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.8645 of outstanding shares, having a total worth of $7.39 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.13 shares of worth $8.69 million or 2.48% of the total outstanding shares. The later fund manager was in possession of 1.01 shares on Mar 31, 2025 , making its stake of worth around $7.73 million in the company or a holder of 2.21% of company’s stock.
